H. Lundbeck A/S (LON:0ND5)
United Kingdom · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 6.48B +28.2% |
| Revenue (ttm) | 2.99B +10.4% |
| Net Income | 453.21M +14.7% |
| EPS | 0.44 +14.7% |
| Shares Out | n/a |
| PE Ratio | 15.03 |
| Forward PE | 8.96 |
| Dividend | 0.13 (1.99%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 96,089 |
| Open | 56.45 |
| Previous Close | 56.55 |
| Day's Range | 55.45 - 59.90 |
| 52-Week Range | 35.56 - 59.55 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
H. Lundbeck Quarterly report: Q3 2026
H. Lundbeck has published its Q3 2026 quarterly earnings report on November 12, 2026.
H. Lundbeck Quarterly report: Q3 2026
H. Lundbeck has published its Q3 2026 quarterly earnings report on November 11, 2026.
Lundbeck hikes annual forecasts as migraine drug powers earnings beat
Danish drugmaker Lundbeck raised its full-year sales and profit forecasts on Tuesday after third-quarter earnings beat expectations, citing strong demand for its migraine treatment Vyepti in the Uni...
Lundbeck raises full-year guidance as 9M revenue grows +13% CER (+11% CER underlying) and adjusted EBITDA +19% CER, led by Vyepti®
VALBY, Denmark, Nov. 10, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +13% CER[1] (+9% DKK) to DKK 20,191 million in the first nine months of 2026, with all regions contributin...
Lundbeck raises financial guidance for 2026
VALBY, Denmark, Nov. 10, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) raises its full-year 2026 guidance for revenue and adjusted EBITDA growth at constant exchange rates (CER).
Changes to the Board of Directors of H. Lundbeck A/S
Dorothea Wenzel, Chair of the Board, has informed the Board that she will step down in connection with the Annual General Meeting in 2027. Following the AGM, Lundbeck's Board intends to appoint Lars ...
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and toler...
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple s...
Lundbeck's Phase IV Trial Of Eptinezumab Meets Primary Goal In Migraine After Prior CGRP Therapy
(RTTNews) - H. Lundbeck A/S (HLBBF), a biopharmaceutical company, announced positive results from the Phase IV THRIVE trial evaluating eptinezumab in adults with migraine who had an inadequate respons...
Lundbeck Reports Positive Phase IV THRIVE Results For Eptinezumab In Migraine
(RTTNews) - H. Lundbeck A/S (HLBBF) announced headline results from the Phase IV THRIVE trial evaluating eptinezumab, an investigational humanised monoclonal antibody administered intravenously, in ad...
Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab Results prov...
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
Lundbeck exploring acquisition of Xeris, Bloomberg reports
Lundbeck (HLBBF) (HLBFF) has expressed interest in acquiring Xeris Biopharma (XERS), Michelle Davis, Vinicy Chan and Crystal Tse of Bloomberg report, citing people familiar with the matter. Lundbeck h...
Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters
The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships. The move is part of Lundbeck'...
Lundbeck upgraded to Buy from Neutral at UBS
UBS upgraded Lundbeck (HLBBF) to Buy from Neutral with a price target of DKK 52, up from DKK 45. The firm cites its high conviction in bexicaserin for the upgrade.
Lundbeck Receives Marketing Authorization For Vyepti In Japan For The Prevention Of Migraine Attacks
(RTTNews) - H. Lundbeck A/S (HLUKF.OB) has received marketing authorization in Japan for Vyepti (eptinezumab), marking a key milestone for the company and expanding preventive migraine treatment optio...
Lundbeck Completes DEEp SEA Randomization; Phase III Bexicaserin Trial In Dravet Syndrome Advances
(RTTNews) - H. Lundbeck A/S (HLUNb.CO, HLUKF.OB) announced that the last patient has been randomized in DEEp SEA, its global Phase III trial evaluating investigational bexicaserin in children and adul...
Lundbeck downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Niall Alexander downgraded Lundbeck (HLBBF) to Sell from Hold with a price target of DKK 36, down from DKK 40. The firm cites headwinds for Rexulti and…
Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome1 Completion of randomization m...
Lundbeck Secures FDA Orphan Drug Designation For Asedebart In Cushing's Syndrome
(RTTNews) - Lundbeck A/S announced that the U.S. FDA has granted Orphan Drug Designation to its investigational antibody Asedebart (Lu AG13909) for the treatment of endogenous Cushing's syndrome.
The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogeno...
H. Lundbeck Quarterly report: Q2 2026
H. Lundbeck has published its Q2 2026 quarterly earnings report on August 21, 2026.
H. Lundbeck Slides: Q2 2026
H. Lundbeck has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
H. Lundbeck Earnings Call Transcript: Q2 2026
Strong H1 2026 results with 16% revenue growth and robust performance from VYEPTI and REXULTI. Guidance for the full year is maintained, with expectations to trend towards the upper end, supported by a strengthened pipeline and disciplined capital allocation.
H. Lundbeck Quarterly report: Q2 2026
H. Lundbeck has published its Q2 2026 quarterly earnings report on August 19, 2026.